Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells 1,500 Shares

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the transaction, the chief executive officer now owns 439,744 shares in the company, valued at $53,785,088.64. The trade was a 0.34 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jazz Pharmaceuticals Trading Down 0.1 %

Shares of JAZZ stock traded down $0.10 during trading hours on Wednesday, hitting $121.53. The company had a trading volume of 499,729 shares, compared to its average volume of 501,075. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $134.17. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The company’s fifty day moving average is $122.60 and its 200 day moving average is $116.32. The stock has a market capitalization of $7.35 billion, a PE ratio of 17.12, a price-to-earnings-growth ratio of 0.90 and a beta of 0.56.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the company. CWA Asset Management Group LLC acquired a new position in Jazz Pharmaceuticals in the 3rd quarter valued at about $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after purchasing an additional 100,112 shares in the last quarter. Centre Asset Management LLC acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $9,335,000. Pacer Advisors Inc. grew its stake in shares of Jazz Pharmaceuticals by 15.3% in the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after acquiring an additional 278,465 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock worth $124,208,000 after purchasing an additional 48,708 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. TD Cowen dropped their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Royal Bank of Canada reiterated an “outperform” rating and set a $179.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $163.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Finally, Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.